Pablo Umaña is Head of Cancer Immunotherapy Discovery at pRED, Roche. He obtained his PhD in Chemical Engineering and Biology from the California Institute of Technology in 1998 carrying out experimental work at ETH Zurich. In 2001 co-founded GlycArt Biotechnology AG in Zurich, Switzerland, a company spinning out of research carried out at the ETH Zurich, and headed its research since the company’s foundation. To date he continues to lead research at the Roche Innovation Center Zurich as part of the Pharma Research and Early Development (pRED) organization within Roche, after GlycArt was acquired by Hoffmann La Roche AG in 2005.

He led the team that discovered and initially developed GAZYVA, a novel Type II CD20 antibody for the treatment of B-cell malignancies, currently approved for the treatment of 1L CLL and fNHL. He has also led the research for the generation and initial development of Roche-pRED’s tumor-targeted-T-cell bispecific, -immunocytokine and -immunomodulator platforms and drug candidates in the field of cancer immunotherapy, including pRED’s T cell bispecific antibody glofitatmab, currently in PhIII clinical trials for aggressive lymphoma.